(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.95%) $83.05
(-1.16%) $1.619
(-0.30%) $2 340.10
(-0.11%) $27.51
(0.44%) $926.20
(-0.15%) $0.933
(-0.14%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
1.34% HKD 34.05
Live Chart Being Loaded With Signals
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments...
Stats | |
---|---|
Volumen de hoy | 609 700 |
Volumen promedio | 2.59M |
Capitalización de mercado | 45.41B |
EPS | HKD0.562 ( 2023-09-30 ) |
Last Dividend | HKD0.616 ( 2023-05-25 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 13.46 |
ATR14 | HKD0.178 (0.52%) |
Volumen Correlación
Hangzhou Tigermed Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hangzhou Tigermed Correlación - Moneda/Commodity
Hangzhou Tigermed Finanzas
Annual | 2023 |
Ingresos: | HKD7.38B |
Beneficio Bruto: | HKD2.85B (38.58 %) |
EPS: | HKD2.34 |
FY | 2023 |
Ingresos: | HKD7.38B |
Beneficio Bruto: | HKD2.85B (38.58 %) |
EPS: | HKD2.34 |
FY | 2022 |
Ingresos: | HKD7.09B |
Beneficio Bruto: | HKD2.81B (39.64 %) |
EPS: | HKD2.32 |
FY | 2021 |
Ingresos: | HKD5.21B |
Beneficio Bruto: | HKD2.27B (43.55 %) |
EPS: | HKD3.31 |
Financial Reports:
No articles found.
Hangzhou Tigermed Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.616 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.362 | 2021-05-25 |
Last Dividend | HKD0.616 | 2023-05-25 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD1.557 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.54 | -- |
Div. Sustainability Score | 8.20 | |
Div.Growth Potential Score | 5.20 | |
Div. Directional Score | 6.70 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3808.HK | Ex Dividend Junior | 2023-07-04 | Annually | 0 | 0.00% | |
1696.HK | Ex Dividend Junior | 2023-08-24 | Annually | 0 | 0.00% | |
0730.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
2283.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1270.HK | Ex Dividend Knight | 2023-05-16 | Annually | 0 | 0.00% | |
0323.HK | No Dividend Player | 2023-06-21 | Sporadic | 0 | 0.00% | |
6055.HK | Ex Dividend Knight | 2023-06-13 | Annually | 0 | 0.00% | |
1821.HK | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
0856.HK | Ex Dividend Junior | 2023-05-31 | Annually | 0 | 0.00% | |
0010.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.274 | 1.500 | 4.52 | 6.77 | [0 - 0.5] |
returnOnAssetsTTM | 0.0682 | 1.200 | 7.73 | 9.27 | [0 - 0.3] |
returnOnEquityTTM | 0.0978 | 1.500 | -0.0245 | -0.0367 | [0.1 - 1] |
payoutRatioTTM | 0.291 | -1.000 | 7.09 | -7.09 | [0 - 1] |
currentRatioTTM | 2.74 | 0.800 | 1.295 | 1.036 | [1 - 3] |
quickRatioTTM | 2.71 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.793 | 1.500 | 1.151 | 1.727 | [0.2 - 2] |
debtRatioTTM | 0.114 | -1.500 | 8.10 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8 465.38 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.951 | 2.00 | 9.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.589 | 2.00 | 9.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.161 | -1.500 | 9.35 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.386 | 1.000 | 6.90 | 6.90 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.337 | 1.000 | 5.26 | 5.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.499 | 1.000 | 8.34 | 8.34 | [0.2 - 2] |
assetTurnoverTTM | 0.249 | 0.800 | -1.675 | -1.340 | [0.5 - 2] |
Total Score | 8.20 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.30 | 1.000 | 8.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0978 | 2.50 | -0.0157 | -0.0367 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.589 | 2.00 | 9.47 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.980 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.951 | 2.00 | 9.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.291 | 1.500 | 7.09 | -7.09 | [0 - 1] |
pegRatioTTM | 0.152 | 1.500 | -2.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.229 | 1.000 | 6.78 | 0 | [0.1 - 0.5] |
Total Score | 5.20 |
Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico